anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Puccinia coronata f. sp. avenae (Pca) is an important foliar pathogen of oat which causes crown rust disease. The virulence profile of 48 Pca isolates derived from different locations in Australia was characterized using a collection of oat lines often utilized in rust surveys in the United States and Australia. This analysis indicates that Pca populations in Eastern Australia are broadly virulent, which contrasts with the population in Western Australia (WA). Several oat lines/Pc genes are effective against all rust samples collected from WA, suggesting they may provide useful resistance in this region if deployed in combination. We identified 19 lines from the United States oat differential set that display disease resistance to Pca in WA, with some in agreement with previous rust survey reports. We adopted the 10-letter nomenclature system to define oat crown rust races in Australia and compare the frequency of those virulence traits to published data from the United States. Based on this nomenclature, 42 unique races were detected among the 48 isolates, reflecting the high diversity of virulence phenotypes for Pca in Australia. Nevertheless, the Pca population in the United States is substantially more broadly virulent than that of Australia. Close examination of resistance profiles for the oat differential set lines after infection with Pca supports hypotheses of allelism or redundancy among Pc genes or the presence of several resistance genes in some oat differential lines. These findings illustrate the need to deconvolute the oat differential set using molecular tools.[Formula: see text] Copyright © 2024 The Author(s). This is an open access article distributed under the CC BY-NC-ND 4.0 International license.
A transgenic animal model for arthritis is disclosed. The arthritic condition results from genetic (or immunologic) manipulations that result in the T cell receptor (TCR) repertoire of the animal being substantially limited relative to the TCR repertoire of a wildtype control animal. The TCR repertoire of the arthritic animal, albeit limited, is functionally viable. In a preferred embodiment, the invention relates to transgenic arthritic mice wherein arthritis results from (1) a transgenic allele which encodes and expresses TCR  alpha  and  beta  subunits that combine in T lymphocytes of the transgenic animal to form a TCR that recognizes an antigen comprising one or more epitopes of an oligopeptide derived from amino acids 41-61 of bovine pancreatic ribonuclease and/or (2) polypeptide arthritogenic self antigens derived from endogenous proteins. The transgenic arthritic mice of the invention provides an animal model which faithfully mimics rheumatoid arthritis and by which human arthritogenic and therapeutic anti-arthritic compositions are evaluated. Also provided herein are therapeutic oligopeptides derived from the variable regions of the TCRs of the transgenes of the invention and/or from the amino acid sequence of proteins comprising endogenous polypeptide arthritogenic antigens.
Rectal cancer surgery represents challenges due to its location. To overcome them and minimize the risk of anastomosis-related complications, some technical maneuvers or even a diverting ileostomy may be required. One of these technical steps is the mobilization of the splenic flexure (SFM), especially in medium/low rectal cancer. High-tie vascular ligation may be another one. However, the need of these maneuvers may be controversial, as especially SFM may be time-consuming and increase the risk of iatrogenic. The objective is to present the short- and long-term outcomes of a low-tie ligation combined with no SFM in robotic low anterior resection (LAR) for mid- and low rectal cancer as a standardized technique. A retrospective observational single-cohort study was carried out at Reina Sofia University Hospital, Cordoba, Spain. 221 robotic rectal resections between Jul-18th-2018 and Jan-12th-2023 were initially considered. After case selection, 80 consecutive robotic LAR performed by a single surgeon were included. STROBE checklist assessed the methodological quality. Histopathological, morbidity and oncological outcomes were assessed. Anastomotic stricture occurrence and distance to anal verge were evaluated after LAR by rectosigmoidoscopy. Variables related to the ileostomy closure such as time to closure, post-operative complications or hospital stay were also considered. The majority of patients (81.2%) presented a mid-rectal cancer and the rest, lower location (18.8%). All patients had adequate perfusion of the anastomotic stump assessed by indocyanine green. Complete total mesorectal excision was performed in 98.8% of the patients with a lymph node ratio < 0.2 in 91.3%. The anastomotic leakage rate was 5%. One patient (1.5%) presented local recurrence. Anastomosis stricture occurred in 7.5% of the patients. The limitations were small cohort and retrospective design. The non-mobilization of the splenic flexure with a low-tie ligation in robotic LAR is a feasible and safe procedure that does not affect oncological outcomes.
PURPOSE: To obtain an immunosuppressant and an antiinflammatory agent, having immunosuppressive and antiinflammatory actions with slight adverse effects and useful as a therapeutic agent for diseases in which immune respnse participates. CONSTITUTION: The immunosuppressant and antiinflammatory agent contain demethylzeylastral, isolated from a root bark of a crude drug Tripterygium wilfordii Hook. f. and represented by the formula active ingredient. The daily dose of the compound is preferably 10 mg to 1 g as an oral agent and preferably 5 to 250 mg as a parenteral agent. The compound is obtained by a method for refluxing, e.g. 10 kg root bark of the Tripterygium wilfordii Hook. f. with ethyl acetate twice under heating, filtering the resultant mixture, providing 287.55 g ethyl acetate essence from the prepared filtrate, dissolving the resultant essence in acetone, adding AVICEL (R) (manufactured by Asahi Chemical Industry Co., Ltd.) thereto, drying the prepared mixture, then treating the dried mixture by a column chromatography with the AVICEL (R), eluting the adsorbed substance with n-hexane, fording 192.45 g essence from the eluted part of n hexane-acetone, dissolving the essence in methanol, treating the resultant solution by a column chromatography with an MCI get-CHP20P (R) (manufactured by Mitsubishi Chemical Industries, Ltd.), eluting the adsorbed substance with 70%, 80%, 85% and 100% methanol,  providing 25.58% essence from the eluted part with the 85% methanol and crystallizing the resultant essence wiht acetone.
PROBLEM TO BE SOLVED: To obtain the subject pack capable of making the appearance opaque and effectively making skin pores astringent by including a skin pore astringent ingredient except an extract from Hamamelis virginiana L. and an extract from Saxifraga stolonifera Meerburg and a mucilaginous agent. SOLUTION: This pack is obtained by including (A) a skin pore astringent ingredient except an extract from Hamamelis virginiana L. and an extract from Saxifraga stolonifera Meerburg (e.g. Arnica montana L., Aloe or an extract from Rhododendron metternichii Sieb. et Zucc. var. pentamerum Maxim.) and (B) a mucilaginous agent (e.g. polyvinyl alcohol or carrageenan) and preferably (C) a refreshing agent (e.g. menthol) and forming the pack into the shape of a sheet having an opaque appearance. In the above pack, the amounts of the formulated ingredients based on the total amount of the cosmetic part except a support and expressed in terms of solid are preferably 0.001-15 wt.% of the ingredient A and 0.005-1.0 wt.% of the ingredient C. The above pack has opacity so that a printing type of 10 points cannot be deciphered.
A method for treating diabetes mellitus by administering composition providing a gastrin/CCK receptor ligand, e.g. a gastrin, and an EGP receptor ligand, e.g. TGF.alpha., in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin/CCK receptor ligand gene, e.g. a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g. a TGF.alpha. gene.
This is a pilot trial designed to assess safety and immunogenicity of a multivalent conjugate vaccine for use in patients with biochemically relapsed prostate cancer. This trial is based on the results of eight dose-seeking phase I monovalent glycoprotein and carbohydrate conjugate vaccine trials in a patient population with minimal tumor burden despite a rising biomarker, PSA, who have failed primary therapy such as surgery or radiation. We know that a rising PSA is indicative of micrometastatic disease - a state to which the immune system may maximally respond. Based on these trials, we have identified three glycolipid antigens, Globo H, Lewisy and GM2 and three mucin antigens, glycosylated MUC-1, Tn(c), and TF(c) for inclusion into a multivalent trial. As a result of these vaccinations, most patients generated specific high titer IgM and IgG antibodies against the respective antigen-KLH conjugates. Our previous work has shown the monovalent vaccines to be safe with local erythema and edema but minimal systemic toxicities. Our data from approximately 160 men who participated in our earlier monovalent vaccine trials against the aforementioned antigens have shown that a treatment effect in the form of a decline in PSA log slopes compared with pretreatment values could be seen in patients with minimal tumor burden. The multivalent vaccine will consist of the lowest dose of synthetic glycoprotein and carbohydrate antigens shown to elicit high titer IgM and IgG antibodies in patients with biochemically relapsed prostate cancer. A phase III double blind randomized trial with two hundred forty patients is planned based on the safety and immunogenicity data accrued from this pilot trial.

The primary endpoints of this study will be the safety of the vaccine and the humoral response to each of the antigens. The secondary endpoint will be to evaluate post-therapy changes in PSA.
BACKGROUND: Acute heart failure (AHF) in the intensive care unit (ICU) is characterized by its criticality, rapid progression, complex and changeable condition, and its pathophysiological process involves the interaction of multiple organs and systems. This makes it difficult to predict in-hospital mortality events comprehensively and accurately. Traditional analysis methods based on statistics and machine learning suffer from insufficient model performance, poor accuracy caused by prior dependence, and difficulty in adequately considering the complex relationships between multiple risk factors. Therefore, the application of deep neural network (DNN) techniques to the specific scenario, predicting mortality events of patients with AHF under intensive care, has become a research frontier.
METHODS: This research utilized the MIMIC-IV critical care database as the primary data source and employed the synthetic minority over-sampling technique (SMOTE) to balance the dataset. Deep neural network models-backpropagation neural network (BPNN) and recurrent neural network (RNN), which are based on electronic medical record data mining, were employed to investigate the in-hospital death event judgment task of patients with AHF under intensive care. Additionally, multiple single machine learning models and ensemble learning models were constructed for comparative experiments. Moreover, we achieved various optimal performance combinations by modifying the classification threshold of deep neural network models to address the diverse real-world requirements in the ICU. Finally, we conducted an interpretable deep model using SHapley Additive exPlanations (SHAP) to uncover the most influential medical record features for each patient from the aspects of global and local interpretation.
RESULTS: In terms of model performance in this scenario, deep neural network models outperform both single machine learning models and ensemble learning models, achieving the highest Accuracy, Precision, Recall, F1 value, and Area under the ROC curve, which can reach 0.949, 0.925, 0.983, 0.953, and 0.987 respectively. SHAP value analysis revealed that the ICU scores (APSIII, OASIS, SOFA) are significantly correlated with the occurrence of in-hospital fatal events.
CONCLUSIONS: Our study underscores that DNN-based mortality event classifier offers a novel intelligent approach for forecasting and assessing the prognosis of AHF patients in the ICU. Additionally, the ICU scores stand out as the most predictive features, which implies that in the decision-making process of the models, ICU scores can provide the most crucial information, making the greatest positive or negative contribution to influence the incidence of in-hospital mortality among patients with acute heart failure.
Excessive anxiety among elementary age students is common, severely impairs academic, social, and behavioral functioning, and is associated with significant educational and health care costs. Despite the high burden of anxiety, less than half of children with anxiety receive the services they need to succeed in school. School clinicians can and do support these youth, however, their caseloads are high and their time to provide individualized services is limited. Consequently, there is a critical need to expand the network of providers who can assist students with anxiety and address this malleable obstacle to student academic success. Because somatic complaints, such as headaches and stomach aches, are a hallmark feature of excessive anxiety, school nurses are often the first school-based personnel to identify problematic anxiety in students. However, school nurses currently lack training in evidenced-based anxiety reduction interventions. The current study leverages findings from a three-year IES Development award (R305A140694), through which our team developed and assessed the feasibility of training elementary school nurses to use a brief intervention to reduce student anxiety; it was demonstrated that the training and intervention (i.e., Child Anxiety Learning Modules; CALM) was indeed feasible to implement and resulted in positive changes in student outcomes. CALM is now a fully developed intervention with ready-to-use intervention components and materials, training and coaching procedures, and is ready for an initial efficacy evaluation in authentic school settings. Toward that end, the primary purpose of this study is to evaluate the efficacy of CALM in a fully powered randomized controlled trial. CALM will be delivered by elementary school nurses in rural, suburban, and urban elementary schools nationwide to enhance the generalizability of findings across socioeconomic, racial, ethnic, and neighborhood settings (as approximately 80% of schools in the US have a school nurse). The efficacy of CALM will be tested using gold standard methods (e.g., independent evaluators to assess primary outcomes). The study's primary aim is to evaluate the efficacy of CALM, compared to a credible comparison condition (CALM-R; a school nurse delivered relaxation skills only intervention that parallels CALM in time and format) as well as a waitlist control, for reducing anxiety symptoms and improving educational outcomes at post-intervention and a one year follow-up. The secondary aim is to examine the cost effectiveness of CALM relative to CALM-R and the waitlist control. An exploratory aim is to examine potential predictors, moderators, and mediators of student outcomes based on the proposed theory of change. If efficacious, CALM will be the first evidenced-based school nurse delivered intervention to assist youth with excessive anxiety, filling an important gap in current practices.
A long-standing issue concerning synesthesia is whether the trait is continuous or discontinuous with ordinary perception. Here, we found that a substantial proportion of non-synesthetes (>10 % out of >200 unselected participants) spontaneously became aware of their synesthesia by participating in an online survey that forced them to select colors for stimuli that evoke color sensations in synesthetes. Notably, the test-retest consistencies of color sensation in these non-synesthetes were comparable to those in self-claimed synesthetes, revealing their strong though latent synesthetic dispositions. The effect was absent or weak in a matched control survey that did not include the color-picking test. Therefore, the color-picking task likely provided the predisposed "borderline non-synesthetes" with an opportunity to dwell on their tendency toward synesthesia and allowed their subconscious sensations to become conscious ones. The finding suggests that the general population has a continuum of synesthetic disposition that encompasses both synesthetes and non-synesthetes.
The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
FIELD: agriculture, veterinary science. SUBSTANCE: vaccine has bacterial mass of new vaccine strain Brucella abortus 75/79AB - ДЕП ВГНКИ. as an antigen. Vaccine has gelatin as a stabilizing agent also. Use of new vaccine ensures to increase effectiveness of antibrucellosis measures by 1.5-2 times. Vaccine is used for specific prophylaxis of brucellosis in cattle. EFFECT: broadened assortment of agents for brucellosis prophylaxis, enhanced effectiveness. 3 tbl, 4 ex
The present invention relates to medicine for treating chronic pelvic inflammation and a preparing method thereof, which belong to the field of traditional Chinese medicine. The present invention is prepared from raw medicinal materials of 170 to 210 portions of angelica, 170 to 210 portions of red sage root, 95 to 135 portions of red peony root, 95 to 135 portions of corydalis tuber, 95 to 135 portions of prism tuber, 95 to 135 portions of zedoary, 95 to 135 portions of flavescent sophora root, 95 to 135 portions of phellodendron, 95 to 135 portions of glabrous greenbrier rhizome and 55 to 95 portions of nutgrass galingale rhizome by weight. The raw medicinal materials are put in an extracting tank with a volatile oil extractor, and are decocted for three times by adding water. The extracted volatile oil is preserved in another device, and the decoction liquid is merged and filtered. Filtrate is concentrated until the relative density is from 1.10 to 1.15 at 20DEG C, and is stood for 24 hours by adding ethanol, and ethanol is recovered until no ethanol flavor exists. The extracted volatile oil is dissolved by a little ethanol, and is sprayed in powder. The medicine of the present invention has conspicuous efficiency of promoting blood circulation for removing blood stasis, clearing away heat, promoting diuresis, eliminating mass and alleviating pain. The present invention has good preventing and curative effects for pelvic inflammatory disease and annexitis.
Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
BACKGROUND: Pseudomonas aeruginosa is a common pathogen that contributes to progressive lung disease in cystic fibrosis (CF). Genetic factors other than CF-causing CFTR (CF transmembrane conductance regulator) variations contribute ∼85% of the variation in chronic P. aeruginosa infection age in CF according to twin studies, but the susceptibility loci remain unknown. Our objective is to advance understanding of the genetic basis of host susceptibility to P. aeruginosa infection.
MATERIALS AND METHODS: We conducted a genome-wide association study of chronic P. aeruginosa infection age in 1037 Canadians with CF. We subsequently assessed the genetic correlation between chronic P. aeruginosa infection age and lung function through polygenic risk score (PRS) analysis and inferred their causal relationship through bidirectional Mendelian randomisation analysis.
RESULTS: Two novel genome-wide significant loci with lead single nucleotide polymorphisms (SNPs) rs62369766 (chr5p12; p=1.98×10-8) and rs927553 (chr13q12.12; p=1.91×10-8) were associated with chronic P. aeruginosa infection age. The rs62369766 locus was validated using an independent French cohort (n=501). Furthermore, the PRS constructed from CF lung function-associated SNPs was significantly associated with chronic P. aeruginosa infection age (p=0.002). Finally, our analysis presented evidence for a causal effect of lung function on chronic P. aeruginosa infection age (β=0.782 years, p=4.24×10-4). In the reverse direction, we observed a moderate effect (β=0.002, p=0.012).
CONCLUSIONS: We identified two novel loci that are associated with chronic P. aeruginosa infection age in individuals with CF. Additionally, we provided evidence of common genetic contributors and a potential causal relationship between P. aeruginosa infection susceptibility and lung function in CF. Therapeutics targeting these genetic factors may delay the onset of chronic infections, which account for significant remaining morbidity in CF.
PROBLEM TO BE SOLVED: To obtain the subject lotion having a high emollient effect and an excellent drabness preventing effect on skin by adding a specific α-amino acid derivative and carboxylic acid ester to a specified cholesterol ester inclusion substance. SOLUTION: This lotion includes (A) a cholesterol ester inclusion substance obtained by including a cholesterol ester (e.g. an ester of cholesterol and a higher fatty acid such as myristic acid, etc.), in a hydroxyalkylated cyclodextrin (hereinafter HACD; e.g. hydroxyethylated cyclodextrin, etc.), (e.g. the amount ratio of HACD to the cholesterol ester is preferably 99:1 to 90:10) and (B) an α-amino acid derivative of the formula (R1 is H or a 1-6C alkyl; R2 and R3 are each H, a 1-6C alkyl or an acyl), its salt, carboxylic acid ester and its quaternary ammonium in the ratio of 0.01-20.0 wt.% of the component A and 0.001-10.0 wt.% of the component B.